Immunotherapy for early triple negative breast cancer: research agenda for the next decade
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapy for early triple negative breast cancer: research agenda for the next decade
Authors
Keywords
-
Journal
npj Breast Cancer
Volume 8, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-02-18
DOI
10.1038/s41523-022-00386-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial
- (2021) Thomas Bachelot et al. NATURE MEDICINE
- Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials
- (2021) Paolo Tarantino et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
- (2021) Larissa A. Korde et al. JOURNAL OF CLINICAL ONCOLOGY
- The Global Landscape of Treatment Standards for Breast Cancer
- (2021) Dario Trapani et al. JNCI-Journal of the National Cancer Institute
- Tumor mutational burden as a predictor of immunotherapy response in breast cancer
- (2021) Tess A. O’Meara et al. Oncotarget
- Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
- (2021) Karthik Dhatchinamoorthy et al. Frontiers in Immunology
- Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors – An analysis of 2765 patients from neoadjuvant clinical trials
- (2021) Sonia L. Villegas et al. EUROPEAN JOURNAL OF CANCER
- Breast cancer
- (2021) Sibylle Loibl et al. LANCET
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
- (2021) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- How to use liquid biopsies to treat patients with cancer
- (2021) L. De Mattos-Arruda et al. ESMO Open
- VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC
- (2021) P. Schmid et al. ANNALS OF ONCOLOGY
- Outcome of breast cancer patients with low hormone receptor positivity: analysis of a 15-year population-based cohort
- (2021) S. Schrodi et al. ANNALS OF ONCOLOGY
- Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer
- (2021) Paula I. Gonzalez-Ericsson et al. CLINICAL CANCER RESEARCH
- Managing side effects of immune checkpoint inhibitors in breast cancer
- (2021) Carmen Criscitiello et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).
- (2021) Sibylle Loibl et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
- (2021) Andrew N.J. Tutt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for Early Triple-Negative Breast Cancer
- (2020) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- It Is Time to Talk About Fertility and Immunotherapy
- (2020) Narjust Duma et al. ONCOLOGIST
- Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
- (2020) Rita Nanda et al. JAMA Oncology
- 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)†
- (2020) F. Cardoso et al. ANNALS OF ONCOLOGY
- Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
- (2020) Elizabeth A Mittendorf et al. LANCET
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
- (2020) Javier Cortes et al. LANCET
- Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer
- (2020) Carolyn Cullinane et al. JAMA Network Open
- Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival
- (2020) M.J.M. Magbanua et al. ANNALS OF ONCOLOGY
- Circulating tumor DNA analysis in breast cancer: is it ready for prime-time?
- (2019) Giuseppe Buono et al. CANCER TREATMENT REVIEWS
- Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers
- (2019) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials
- (2019) Richard Gray et al. LANCET
- Defining the immunogram of breast cancer: a focus on clinical trials
- (2019) Paolo Tarantino et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer – clinical results and biomarker analysis of GeparNuevo study
- (2019) S Loibl et al. ANNALS OF ONCOLOGY
- Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts
- (2019) Katherine E. Hutchinson et al. CLINICAL CANCER RESEARCH
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Peter Schmid et al. LANCET ONCOLOGY
- Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy
- (2019) J H Park et al. ANNALS OF ONCOLOGY
- Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
- (2018) Sibylle Loibl et al. LANCET ONCOLOGY
- Immunological differences between primary and metastatic breast cancer
- (2018) B Szekely et al. ANNALS OF ONCOLOGY
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
- (2017) Norikazu Masuda et al. NEW ENGLAND JOURNAL OF MEDICINE
- The "cancer immunogram"
- (2016) C. U. Blank et al. SCIENCE
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- (2014) Patricia Cortazar et al. LANCET
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More